Claims
- 1. A compound having the formula ##STR17## or a pharmaceutically acceptable salt thereof wherein R.sub.1 is hydrogen, alkyl, alkanoyl, alkenyl, arylcarbonyl, heteroarylcarbonyl or ##STR18## R.sub.2 and R.sub.3 are each independently hydrogen, alkyl, cycloalkyl or arylalkyl or R.sub.2 and R.sub.3 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl, or morpholinyl;
- R.sub.4 and R.sub.5 are each independently hydrogen, halogen, alkyl, alkoxy, aryloxy, arylalkoxy, diarylalkoxy, arylalkyl, cyano, hydroxy, alkanoyloxy, ##STR19## fluoro substituted alkoxy, fluoro substituted alkyl, (cycloalkyl)alkoxy, --NO.sub.2, --NX.sub.3 X.sub.4, --S(O).sub.m alkyl, --S(O).sub.m aryl, ##STR20## n is 2 or 3; m is 0, 1 or 2;
- X.sub.1 and X.sub.2 are each independently hydrogen, alkyl, aryl or heteroaryl, or X.sub.1 and X.sub.2 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl or morpholinyl;
- X.sub.3 and X.sub.4 are each independently hydrogen, alkyl, alkanoyl, arylcarbonyl, heteroacrylcarbonyl, or ##STR21## X.sub.5 is hydroxy, alkoxy, aryloxy, amino, alkylamino or dialkylamino; and
- X.sub.6 is alkyl, alkoxy or aryloxy; with the proviso that if R4 is a 7-alkyl group, it must have a tertiary carbon atom bonded to the ring;
- wherein the term "aryl" refers to phenyl and phenyl substituted with 1, 2 or 3 amino, alkylamino, dialkylamino, nitro, halogen, hydroxyl, trifluoromethyl, alkyl or 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyloxy, carbamoyl, or carboxyl groups;
- the term "heteroaryl" refers to pyridinyl, pyrrolyl, imidazolyl, furyl, thienyl, or thiazolyl;
- the terms "alkyl" and "alkoxy" refers to groups having 1 to 10 carbon atoms;
- the term "alkenyl" refers to groups having 2 to 10 carbon atoms;
- the term "alkanoyl" refers to groups having 2 to 11 carbon atoms; and
- the term "cycloalkyl" refers to groups having 3, 4, 5, 6 or 7 carbon atoms.
- 2. A compound in accordance with claim 1 wherein R.sub.4 and R.sub.5 are each independently hydrogen, halogen, alkyl, alkoxy, aryloxy, arylalkoxy, arylalkyl, hydroxy, alkanoyloxy, ##STR22## difluoromethoxy, trifluoromethyl, --NX.sub.3 X.sub.4, 13 S(O).sub.m aklyl or --S(O).sub.m aryl;
- X.sub.1 and X.sub.2 are each independently hydrogen, alkyl or heteroaryl; and
- X.sub.3 and X.sub.4 are each independently alkyl, alkanoyl, arylcarbonyl, heteroarylcarbonyl, or ##STR23##
- 3. A compound in accordance with claim 1 wherein R.sub.2 and R.sub.3 are each independently alkyl or cycloalkyl.
- 4. A compound in accordance with claim 1 wherein R.sub.1 is hydrogen.
- 5. A compound in accordance with claim 1 wherein R.sub.1 is alkyl.
- 6. A compound in accordance with claim 1 wherein R.sub.1 is alkanoyl, alkenyl, arylcarbonyl, heteroarylcarbonyl or ##STR24##
- 7. A compound in accordance with claim 6 wherein R.sub.1 is alkanoyl.
- 8. A compound in accordance with claim 7 wherein R.sub.1 is acetyl.
- 9. A compound in accordance with claim 1 wherein R.sub.2 and R.sub.3 are each alkyl.
- 10. A compound in accordance with claim 9 wherein R.sub.2 and R.sub.3 are each methyl.
- 11. A compound in accordance with claim 1 wherein R.sub.2 and R.sub.3 are each cycloalkyl.
- 12. A compound in accordance with claim 1 wherein R.sub.2 and R.sub.3 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl or morpholinyl.
- 13. A compound in accordance with claim 1 wherein R.sub.4 is hydrogen.
- 14. A compound in accordance with claim 1 wherein R.sub.4 is halogen.
- 15. A compound in accordance with claim 1 wherein R.sub.4 is chlorine and is located in the 7-position of the benzazepine nucleus.
- 16. A compound in accordance with claim 1 wherein R.sub.4 is trifluoromethyl and is located in the 6-position of the benzazepine nucleus.
- 17. A compound in accordance with claim 1 wherein R.sub.4 is trifluoromethyl and is located in the 7-position of the benzazepine nucleus.
- 18. A compound in accordance with claim 1 wherein R.sub.5 is alkoxy.
- 19. A compound in accordance with claim 1 wherein R.sub.5 is methoxy and is located in the 4-position of the phenyl ring to which it is attached.
- 20. A compound in accordance with claim 1 wherein n is 2.
- 21. A compound in accordance with claim 1 wherein n is 3.
- 22. The d-cis enantiomer of a compound of claim 1.
- 23. A compound in accordance with claim 1 wherein R.sub.1 is alkanoyl, R.sub.2 and R.sub.3 are each alkyl, R.sub.4 is 6- or 7-trifluoromethyl, R.sub.5 is alkoxy and is located in the 4-position of the ring to which it is attached, and n is 2.
- 24. The compound in accordance with claim 1, (cis)-3-(acetyloxy)-7-chloro-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-2H 1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 25. The compound in accordance with claim 1, (cis)-3-(acetyloxy)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-2H-1-benzazepin-2-one or a pharmaceutically acceptable salt thereof.
- 26. The compound in accordance with claim 1, (trans)-3-(acetyloxy)-1-2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-2H-1-benzazepin-2-one, or a pharmaceutically acceptable salt thereof.
- 27. The compound in accordance with claim 1, (cis)-3-(acetyloxy)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-7-(trifluoromethyl)-2H-1-benzazepin-2-one, or a pharmaceutically acceptable salt thereof.
- 28. The compound in accordance with claim 1, (cis)-3-(acetyloxy)-7-(methoxy)-1-2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-2H 2-one, or a pharmaceutically acceptable salt thereof.
- 29. The compound in accordance with claim 1, (d-cis)-3-(acetyloxy)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-6-(trifluoro-methyl)-2H-1-benzazepin-2-one, or a pharmaceutically acceptable salt thereof.
- 30. The compound in accordance with claim 1, (d-cis)-3-(acetyloxy)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-1-[2-(methylamino)ethyl]-6-(trifluoromethyl)-2H-1-benzazepin-2-one, or a pharmaceutically acceptable salt thereof.
Parent Case Info
This application is a continuation-in-part of U.S. patent application Ser. No. 935,995, filed Nov. 28, 1986, and now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 800,936, filed Nov. 22, 1985, and now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 743,841, filed June 12, 1985, and now abandoned.
US Referenced Citations (4)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0205334 |
Dec 1986 |
EPX |
Non-Patent Literature Citations (4)
Entry |
Yabana et al., J. Cardiovascular Pharm., vol. 7, p. 152, (1985). |
Schoemaker et al., J. Cardiovascular Pharm., vol. 9, p. 173, (1987). |
Chem. Pharm. Bull., vol. 33, pp. 634-641, (1985). |
Goodman and Gilman's, "The Pharmacological Basis of Therapeutics", Seventh Edition, (MacMillan), (1985), pp. 816-819. |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
935995 |
Nov 1986 |
|
Parent |
800936 |
Nov 1985 |
|
Parent |
743841 |
Jun 1985 |
|